PLUS THERAPEUTICS PSTV 深 沪
等待开盘 03-26 09:30:00 美东时间
0.2459
+0.006
+2.50%
华盛通- 最 高0.2538
- 今 开0.2438
- 成交量 332.74万股
- 最 低 0.24
- 昨 收 0.2399
- 总市值 4386.15万
- 52周最高 1.22
- 市盈率 静 --
- 换手率 1.87%
- 52周最低 0.1634
- 委 比 -97.30%
- 总股本 1.78亿
- 历史最高 343.35
- 量 比 0.96
- 振 幅 5.75%
- 历史最低 0.1634
- 每 手 1
- 风险率 0.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Plus Therapeutics to present CNSide analysis showing 40% leptomeningeal metastases cost reduction at ISPOR 2026
Plus Therapeutics to present CNSide analysis showing 40% leptomeningeal metastases cost reduction at ISPOR 2026 Plus Therapeutics is scheduled to present a health economics poster at the ISPOR 2026 Annual Meeting on May 17-20, 2026, in Philadelphia, Pennsylvania. The poster reports a cost-of-care an
03-19 19:31
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
Plus Therapeutics announced a health economics study showing that earlier detection of leptomeningeal metastases (LM) using CNSide® CSF Assay may reduce LM-related healthcare costs by about 40% through improved treatment precision and reduced hospitalizations. The findings will be presented at the ISPOR 2026 Annual Meeting. CNSide provides early actionable information, and the analysis highlights substantial cost savings and improved patient outc...
03-19 11:30
Plus Therapeutics Announces New Category III CPT Code for REYOBIQ Convection-Enhanced Delivery
Plus Therapeutics Announces New Category III CPT Code for REYOBIQ Convection-Enhanced Delivery Plus Therapeutics Inc. said the American Medical Association’s CPT Editorial Panel approved a new Category III CPT code to track utilization of convection-enhanced delivery used to administer REYOBIQ for r
02-25 20:30
美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
U.S. RESEARCH ROUNDUP-Applied Materials, Procter & Gamble, RLI
U.S. RESEARCH ROUNDUP-Applied Materials, Procter & Gamble, RLI Jan 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Applied Materials, Procter & Gamble and RLI, on Friday. HIGHLIGHTS * Applied Materials Inc AMAT.O : Be
01-23 15:13
D. Boral Capital Maintains Buy on Plus Therapeutics, Lowers Price Target to $4
D. Boral Capital analyst Jason Kolbert maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lowers the price target from $5 to $4.
01-22 20:41
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
Plus Therapeutics provides a business update, highlighting progress in its REYOBIQ clinical trials and CNSide commercialization. The company aims to scale CNSide and prepare for pivotal trials, supported by a $15 million offering. Key 2026 milestones include optimizing REYOBIQ dosing, completing trials for glioblastoma and pediatric brain cancer, expanding commercial coverage, and launching additional CNS tumor tests.
01-22 12:45
BRIEF-Plus Therapeutics To Provide Business Update On Thursday
BRIEF-Plus Therapeutics To Provide Business Update On Thursday Jan 21 (Reuters) - Plus Therapeutics Inc PSTV.O : PLUS THERAPEUTICS TO PROVIDE BUSINESS UPDATE AND HOST CONFERENCE CALL ON THURSDAY, JANUARY 22, 2026 AT 9:00 A.M. ET Source text: ID:nGNXbhKMkd Further company coverage: PSTV.O (( Reuters.
01-22 06:02
Benzinga Bulls And Bears: TSMC, Rocket Lab, J.B. Hunt — And Space Stocks Soar
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
01-17 21:21
